


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3696)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of InSilico Medicine Cayman TopCo (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board of the Company will be held on Friday, March 27, 2026 for the purposes of considering and approving the annual results of the Group for the year ended December 31, 2025 and the recommendation of a final dividend (if any) and transacting any other business.

By order of the Board

InSilico Medicine Cayman TopCo

Mr. Aleksandrs Zavoronkovs, Ph.D.

Chairman, Executive Director, CEO and CBO

Hong Kong, March 13, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.